【摘要】：近年來(lái),中國(guó)的前列腺癌發(fā)病率逐年上升。大多數(shù)前列腺癌患者在初診時(shí)已處于中晚期,雖然內(nèi)分泌治療在一定時(shí)期內(nèi)可以使病情得到控制與改善,但經(jīng)過18~24個(gè)月的中位緩解期后,絕大多數(shù)患者均進(jìn)展為預(yù)后極差的轉(zhuǎn)移性去勢(shì)抵抗性前列腺癌(metastatic castration-resistant prostate cancer,m CRPC)。mCRPC的治療頗為棘手,迫切需要優(yōu)化其治療策略來(lái)提高療效。目前已有研究表明,新型內(nèi)分泌藥物如醋酸阿比特龍、恩雜魯胺與多西紫杉醇化療可以使mCRPC患者生存獲益,但有關(guān)治療次序的選擇仍存在一定爭(zhēng)議。本文對(duì)mCRPC患者在化療前后接受不同次序的新型內(nèi)分泌藥物治療相關(guān)的臨床研究進(jìn)展進(jìn)行綜述,以期為正確選擇mCRPC治療策略提供依據(jù),進(jìn)而延長(zhǎng)患者的總生存期并提高生活質(zhì)量。
[Abstract]:In recent years, the incidence of prostate cancer in China has increased year by year. The majority of prostate cancer patients are in the middle and late stage at the first visit. Although endocrine therapy can control and improve the disease in a certain period of time, but after 18 ~ 24 months of median remission period, Most of the patients developed into metastatic castrated resistant prostate cancer (metastatic castration-resistant prostate cancer,m CRPC). MCRPC) with poor prognosis. It is urgent to optimize the treatment strategy to improve the curative effect. Studies have shown that new endocrine drugs such as Abigitron Acetate, Enzaluramide and docetaxel chemotherapy can benefit the survival of patients with mCRPC, but the choice of treatment order is still controversial. This article reviews the clinical research progress of patients with mCRPC receiving new endocrine drugs in different order before and after chemotherapy, in order to provide the basis for the correct choice of mCRPC treatment strategy, and then prolong the total life span and improve the quality of life of patients.
【作者單位】： 天津醫(yī)科大學(xué)腫瘤醫(yī)院國(guó)家腫瘤臨床醫(yī)學(xué)研究中心天津市"腫瘤防治"重點(diǎn)實(shí)驗(yàn)室天津市惡性腫瘤臨床醫(yī)學(xué)研究中心;天津醫(yī)科大學(xué)第二醫(yī)院腫瘤科天津市泌尿外科研究所;
【基金】：國(guó)家自然科學(xué)基金資助項(xiàng)目(編號(hào):81572543) 天津市衛(wèi)生行業(yè)重點(diǎn)攻關(guān)項(xiàng)目(編號(hào):14KG141)~~
【分類號(hào)】：R737.25

【相似文獻(xiàn)】

相關(guān)期刊論文 前3條

1 尹絹;寇光;邱元芝;彭樂;陳發(fā)秀;;參芪扶正注射液聯(lián)合內(nèi)分泌藥物治療老年前列腺癌的療效觀察[J];實(shí)用癌癥雜志;2014年01期

2 陸勝康;前列腺癌12例臨床分析[J];中國(guó)腫瘤臨床;1994年07期

3 張立;翁繩美;;前列腺癌內(nèi)分泌藥物治療的現(xiàn)狀與展望[J];海峽藥學(xué);2008年06期

，

本文編號(hào)：2392764